Cellular Biomedicine Group

136 articles about Cellular Biomedicine Group

• ­Cellular Biomedicine Group Executives to Present at CAR-TCR Summit Asia

  6/18/2019

  Cellular Biomedicine Group Inc. announced that several of its executives will participate in the upcoming CAR-TCR Summit Asia to be held in Shanghai, June 19-20, 2019.

• Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China

  6/17/2019

  Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell targeting anti-CD19 treated, relapsed diffuse large B-cell lymphoma and small B-cell lymphoma patients in China, and dosed the first CD19 CAR-T relapsed DLBCL patient.

• Cellular Biomedicine Group to Present at International Society for Cell and Gene Therapy Annual Meeting

  5/29/2019

  Cellular Biomedicine Group, Inc. announced that the Company will feature at the International Society for Cell and Gene Therapy annual meeting being held May 29-June 1, 2019 at the Melbourne Convention and Exhibition Centre.

• Cellular Biomedicine Group to Present at B. Riley FBR Annual Investor Conference

  5/20/2019

  Cellular Biomedicine Group, Inc. announced that Derrick Li, Head of Strategy for the Company, will deliver a presentation on its business strategy to investors at the B. Riley FBR Annual Investor Conference being held at the Beverly Hilton, in Beverly Hills, California.

• Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress

  4/30/2019

  Initiated patient recruitment for Phase I trial of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China

• Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders

  4/29/2019

  Approximately 79% of the Company's outstanding shares were represented at the 2019 Annual Meeting.

• Cellular Biomedicine Group to Report First Quarter 2019 Results and Host Conference Call on May 1, 2019

  4/25/2019

  It will release its financial results for the first quarter ended March 31, 2019 before the market opens on Wednesday, May 1, 2019.

• Cellular Biomedicine Group Upgraded to NASDAQ Global Select Market

  4/23/2019

  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company's securities from the NASDAQ Global Market to the NASDAQ Global Select Market,

• Cellular Biomedicine Group to Participate in Asia Pharma R&D Leaders Summit 2019

  4/15/2019

  Cellular Biomedicine Group, Inc. announced that Tony Liu, CEO for the Company, will participate in the CEO roundtable discussion "Promoting China Innovation & Roundtable Discussion: Development and Commercialization of Next Generation CAR-T Cell Therapy in China" at the Asia Pharma R&D Leaders Summit 2019 to be held on April 16-17 at the Ruijin Intercontinental Hotel in Shanghai, China.

• Cellular Biomedicine Group to Present at Annual BioCentury Future Leaders in the Biotech Industry Conference

  4/5/2019

  26th Annual BioCentury Future Leaders in the Biotech Industry conference, to be held on Friday, April 12th at 3:30 PM ET, at the Millennium Broadway Hotel & Conference Center in New York.

• Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders

  3/28/2019

  Cellular Biomedicine Group Inc. announced that the Annual Meeting of Stockholders will be held on Friday, April 26, 2019.

• Cellular Biomedicine Group to Present at 8th Annual SVB Leerink Global Healthcare Conference

  2/27/2019

  Cellular Biomedicine Group Inc. announced that Derrick Li, Head of Strategy and Investor Relations, will present a Company update at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Friday, March 1st at 11:30 AM EST.

• Cellular Biomedicine Group Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress

  2/20/2019

  Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors

• Cellular Biomedicine Group's AlloJoin® Therapy for Knee Osteoarthritis (KOA) Becomes the First Stem Cell Drug Application Approved in China for Phase II Clinical Trials

  1/17/2019

  Cellular Biomedicine Group, Inc announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell (haMPC) AlloJoin® therapy for Knee Osteoarthritis (KOA) has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial.

• Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)

  1/9/2019

  Cellular Biomedicine Group Inc. today announces the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.

• Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat  Solid Tumors

  10/3/2018

  Cellular Biomedicine Group Inc. today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services.

• Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China

  9/27/2018

  Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.

• Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland

  6/22/2018

  Cellular Biomedicine Group, a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the grand opening of a new research and development center in Gaithersburg, Maryland.

• Cellular Biomedicine Group to Present a Keynote Address at CAR-TCR Summit Asia

  6/21/2018

  Cellular Biomedicine Group Inc. will participate in the upcoming CAR-TCR Summit Asia to be held in Singapore

• Cellular Biomedicine Group Announces $30.6M Investment From Sailing Capital Overseas Investment

  2/5/2018

  As part of the transaction, Sailing will appoint a representative to the Company’s Board of Directors. Cantor Fitzgerald & Co. acted as a financial advisor to the Company.